Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study

Momtazmanesh, Sara; Ansari, Sahar; Izadi, Zahra; Shobeiri, Parnian; Vatankhah, Venus; Seifi, Arash; Ghiasvand, Fereshteh; Bahrami, Mahboobeh; Salehi, Maryam; Noorbala, Ahmad Ali; Akhondzadeh, Shahin

doi:10.1016/j.jpsychores.2023.111389

Cited by 5 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of the studies found, only three were small scale randomized controlled studies. Each one was a controlled study on the efficacy of the H2 antagonist famotidine ( Momtazmanesh et al, 2023 ) or donezepil hydrochloride ( Pooladgar et al, 2023 ), and one investigated the effectiveness of a neuro-meditation program ( Hausswirth et al, 2023 ). A case control study evaluated the efficacy of cognitive remediation therapy ( Palladini et al, 2023 ), a feasibility pilot study was carried out on a personalized computerized cognitive training ( Dunabeitia et al, 2023 ), and one observational pilot study evaluated a multimodal therapy concept with behavioral therapy-oriented, disorder-specific psychotherapy and exercise therapy ( Kupferschmitt et al, 2023 ).…”

Section: Resultsmentioning

confidence: 99%

Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care

Zifko,

Guendling,

Seet

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Although post-COVID-19 syndrome (PCS) with cognitive impairment is increasingly encountered in primary care, evidence-based recommendations for its appropriate management are lacking.Methods: A systematic literature search evaluating the diagnosis and treatment of cognitive impairment associated with PCS was conducted. Practical recommendations for the management of PCS-associated cognitive impairment in primary care are summarized, based on an evaluation of pharmacological plausibility and clinical applications.Results: Currently, the pathology of cognitive impairment associated with PCS remains unclear with no high-quality data to support targeted interventions. Existing treatment approaches are directed towards symptom relief where counseling on the chronicity of the disease and regular reassessments at 4- to 8-week intervals is considered reasonable. Patients should be informed and encouraged to adopt a healthy lifestyle that centers around balanced nutrition and appropriate physical activities. They may also benefit from the intake of vitamins, micronutrients, and probiotics. The administration of Ginkgo biloba extract could offer a safe and potentially beneficial treatment option. Other non-pharmacological measures include physiotherapy, digitally supported cognitive training, and, if indicated, ergotherapy or speech therapy. In most patients, symptoms improve within 8 weeks. If serious, ambiguous, or when new symptoms occur, specialized diagnostic measures such as comprehensive neurocognitive testing or neuroimaging should be initiated. Very few patients would require inpatient rehabilitation.Conclusion: PCS with cognitive impairment is a debilitating condition that could affect daily functioning and reduce work productivity. Management in primary care should adopt a multidisciplinary approach, centering around physical, cognitive, and pharmacological therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care

Zifko,

Guendling,

Seet

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment

Kow

Ramachandram

Hasan

2023

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach

Griffin

2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after the acute period. Postviral fatigue syndromes are recognized with other viral infections and are described after coronavirus disease 2019 (COVID-19). We have a growing number of individuals with symptoms that persist for weeks, months, and years. Here, we share the evidence regarding the abnormalities associated with postacute sequelae of COVID-19 (PASC) and therapeutics. We describe physiological and biochemical abnormalities seen in individuals reporting PASC. We describe the several evidence-based interventions to offer patients. It is expected that this growing understanding of the mechanisms driving PASC and the benefits seen with certain therapeutics may not only lead to better outcomes for those with PASC but may also have the potential for understanding and treating other postinfectious sequelae.

show abstract

Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study

Cited by 5 publications

References 50 publications

Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care

Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment

Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach

Contact Info

Product

Resources

About